Ophthalmic Disease Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, Anti-glaucoma {Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists}), By Dosage Form (Solid, Liquid, & Semisolid), By Disease Indication (Glaucoma {Open Angle Glaucoma, Angle Closure Glaucoma}, Dry Eye Disease, Retinal Diseases {Diabetic Macular Edema, Macular Degeneration}, Allergy & Infections), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), & Regional Forecast, 2026-2034

Last Updated: January 26, 2026 | Format: PDF | Report ID: FBI100441

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2025
2. Pipeline Analysis, By Key Players
3. Patent Snapshot, By Key Players
4. Key Industry Developments – Merges, Acquisitions and Partnerships
5. Regulatory Scenario for Key Countries
6. Reimbursement Scenario for Key Countries
7. Impact of COVID-19 on the Market
Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. U.K
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Viatris Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Novartis AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. AbbVie Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. F. Hoffmann-La Roche Ltd.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Regeneron Pharmaceuticals, Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Santen Pharmaceutical Co., Ltd.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Bayer AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Bausch & Lomb Incorporated
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Merck KGaA
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2025
2. Pipeline Analysis, By Key Players
3. Patent Snapshot, By Key Players
4. Key Industry Developments – Merges, Acquisitions and Partnerships
5. Regulatory Scenario for Key Countries
6. Reimbursement Scenario for Key Countries
7. Impact of COVID-19 on the Market
Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. U.K
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Anti-inflammatory
  2. Anti-infectives
  3. Anti-VEGF
  4. Anti-glaucoma
    1. Beta Blockers
    2. Prostaglandins Analogs
    3. Alpha Adrenergic Agonists
    4. Carbonic Anhydrase Inhibitors
    5. Combination Drugs
    6. Others
  5. Others
2. Market Analysis, Insights and Forecast – By Dosage Form
  1. Solid
  2. Liquid
  3. Semisolid
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Glaucoma
    1. Open Angle Glaucoma
    2. Angle Closure Glaucoma
    3. Others
  2. Dry Eye Disease
  3. Retinal Diseases
    1. Diabetic Macular Edema (DME)
    2. Macular Degeneration (AMD)
    3. Diabetic Retinopathy (DR)
    4. Retinal Vein Occlusion (RVO)
    5. Others
  4. Allergy & Infections
  5. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail & Online Pharmacies
5. Market Analysis, Insights and Forecast – By Country/ Sub-region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles
  1. Viatris Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Novartis AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. AbbVie Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. F. Hoffmann-La Roche Ltd.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Regeneron Pharmaceuticals, Inc.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Santen Pharmaceutical Co., Ltd.
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Bayer AG
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Bausch & Lomb Incorporated
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Merck KGaA
    1. Overview
    2. Products & Services
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: Global Ophthalmic Disease Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034

Figure 3: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025 & 2034

Figure 4: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025 & 2034

Figure 5: Global Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 6: Global Ophthalmic Disease Therapeutics Market Value (USD billion), by Region, 2025 & 2034

Figure 7: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 8: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 9: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034

Figure 10: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025

Figure 11: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 12: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025

Figure 13: North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 14: North America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 15: North America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country, 2025 & 2034

Figure 16: North America Ophthalmic Disease Therapeutics Market Value Share (%), By Country, 2025

Figure 17: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 18: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 19: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034

Figure 20: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025

Figure 21: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 22: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025

Figure 23: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 24: Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 25: Europe Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 26: Europe Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 27: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 28: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 29: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034

Figure 30: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025

Figure 31: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 32: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025

Figure 33: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 34: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 35: Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 36: Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 37: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 38: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 39: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034

Figure 40: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025

Figure 41: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 42: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025

Figure 43: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 44: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 45: Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 46: Latin America Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2025

Figure 49: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2025 & 2034

Figure 50: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2025

Figure 51: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 52: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2025

Figure 53: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 54: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2025

Figure 55: Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034

Figure 56: Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Ophthalmic Disease Therapeutics Market Share (%), By Company, 2025

List of Tables

Table 1: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

Table 2: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034

Table 3: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034

Table 4: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 5: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034

Table 6: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034

Table 7: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 8: Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 9: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

Table 10: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034

Table 11: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034

Table 12: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 13: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034

Table 14: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034

Table 15: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 16: North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034

Table 17: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

Table 18: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034

Table 19: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034

Table 20: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 21: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034

Table 22: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034

Table 23: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 24: Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 25: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

Table 26: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034

Table 27: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034

Table 28: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 29: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034

Table 30: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034

Table 31: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 32: Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 33: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

Table 34: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034

Table 35: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034

Table 36: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 37: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034

Table 38: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034

Table 39: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 40: Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

Table 41: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

Table 42: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2021-2034

Table 43: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034

Table 44: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034

Table 45: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2021-2034

Table 46: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2021-2034

Table 47: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

Table 48: Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 180

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com